Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2025-12-24 @ 11:04 PM
NCT ID:
NCT04273269
Eligibility Criteria:
Inclusion Criteria:
* Documented GM1 gangliosidosis diagnosis based on genotyping confirming the β-gal gene mutations and/or documented deficiency of β-gal enzyme by laboratory testing
* Children with early infantile GM1 gangliosidosis less than 12 months of age with ability to swallow
* Children with late infantile GM1 gangliosidosis less than 3 years of age with ability to sit
Exclusion Criteria:
* Uncontrolled seizure disorder. Patients who are stable on anti-convulsive medications may be included
* More than 40% brain atrophy as measured by MRI total brain volume at screening
* Current participation in a clinical trial of another investigational medicinal product
* Past participation in a gene therapy trial
* History of hematopoietic stem cell transplantation
* Any condition that would contraindicate treatment with immunosuppressant therapy
* Presence of concomitant medical condition or anatomical abnormality precluding lumbar puncture or intracisternal injection
* Presence of any permanent items (e.g., metal braces) precluding undergoing MRI
* History of non-GM1 gangliosidosis medical condition that would confound scientific rigor or interpretation of results
* Rare and unrelated serious comorbidities, e.g., Down syndrome, intraventricular hemorrhage in the new-born period, extreme low birth weight (\<1500 grams) or known bleeding disorders
* Any vaccination 1 month prior to the planned immunosuppressant treatment
* Serology consistent with HIV exposure or consistent with active hepatitis B or C infection
* Grade 2 or higher lab abnormalities for Liver function tests (LFT), bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT), and partial thromboplastin time (PTT), according to CTCAE v5.0
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
3 Years
Study:
NCT04273269
Study Brief:
Protocol Section:
NCT04273269